ArticleThe Journal of small animal practice2026
Increased serum amyloid A and urinary kidney injury marker-1 concentrations in cats with pyelonephritis: a diagnostic accuracy study.
Article in The Journal of small animal practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectivesTo investigate the discriminatory potential of serum amyloid A, neutrophil:lymphocyte ratio, monocyte:lymphocyte ratio and assess renal tubular injury in cats with pyelonephritis. MATERIALS AND
methodsDiagnostic accuracy study using samples from prospectively enrolled cats and stored material. Cats were classified according to diagnosis as pyelonephritis, ureteral obstruction, chronic kidney disease, subclinical bacteriuria, cystitis, or healthy. Serum amyloid A, neutrophil:lymphocyte ratio, monocyte:lymphocyte ratio and urinary kidney injury marker-1 were compared across groups. Receiver operating characteristic curve analysis assessed the performance of inflammatory biomarkers. Serum amyloid A and urinary kidney injury marker-1 were measured consecutively in a subset of cats with pyelonephritis.
resultsSamples from 71 cats (pyelonephritis n = 22, other urological conditions n = 35, healthy n = 14) were included. Median serum amyloid A concentration was significantly higher in cats with pyelonephritis, overlapping minimally with other groups. At a threshold of 49.1 mg/L, serum amyloid A showed a positive likelihood ratio of 32, sensitivity of 0.95 (95% CI: 0.74 to 0.99) and specificity of 0.97 (95% CI: 0.85 to 0.99), outperforming neutrophil:lymphocyte ratio. Serum amyloid A normalised in 12/14 cats post-treatment. Urinary kidney injury marker-1 was elevated in more than 50% of cats with pyelonephritis and ureteral obstruction, significantly higher than in healthy cats and those with subclinical bacteriuria or cystitis. Variation in urinary kidney injury marker-1 was observed during follow-up.
conclusionsAt a threshold of 49 mg/L, serum amyloid A is a highly accurate biomarker for differentiating pyelonephritis from other urological conditions. Elevated urinary kidney injury marker-1 suggests frequent proximal tubular injury. CLINICAL SIGNIFICANCE: Pyelonephritis is challenging to diagnose. Serum amyloid A can improve diagnostic precision and support timely treatment decisions. Urinary kidney injury marker-1 helps identify tubular injury; however, the clinical implications remain to be investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.